Rigshospitalet
Department of Radiation Biology

Anders Toft, Medical Student

Email: anders.toft.02@rh.regionh.dk
Phone:  (+45) 35 45 63 31
Fax: (+45) 35 45 63 01
  
Date of birth:
May 19th, 1990
 
Current position:
Research Year Student

 

 

  

Education:
2006-2009  High school diploma, Nærum High School
2010-2014 Bachelor of Medicine, Copenhagen University
 

Research and Professional Experiences:
2011-2012Research Student, Department of International Health, Immunology and Microbiology, Copenhagen University
2014-Research Student, Department of Radiation Biology, The Finsencenter, Rigshospitalet, Copenhagen University Hospital
 
Conferences and Meetings:
Poster presentation:
2015

The 20th Annual SNO Scientific Meeting and Education Day,San Antonio,USA;Toft A, Urup T1, Christensen IJ,, Michaelsen SR, Grunnet K, Lukram B, Larsen VA, Kosteljanetz M, Lassen U, Broholm H, Poulsen HS;Prognostic and predictive biomarkers in recurrent WHO grade 3 glioma patients treated with bevacizumab and irinotecan.

2015
XI Northern Lights, Neuroscience Symposium on Brain Tumors, Middelfart;
Toft A, Urup T, Grunnet K, Christensen IJ, Michaelsen SR, Broholm H, Larsen VA, Kosteljanetz, Lassen U, Poulsen HS: Prognostic and predictive biomarkers in recurrent WHO grade 3 glioma patients treated with bevacizumab and irinotecan.
 
Oral presentation:
2016 Scandinavian Society of Neuro-Oncology Meeting, Copenhagen: Toft A, Urup T, Grunnet K, Christensen IJ, Michaelsen SR, Broholm H, Lukram B, Larsen VA, Kosteljanetz M, Lassen U, Poulsen HS; Prognostic and Predictive Biomarkers in Recurrent WHO Grade III Maglingneant Glioma Patients Treated with Bevacizumab and Irinotecan.

 
Publications with peer-review:
2014
Brochmann RP, Toft A, Ciofu O, Briales A, Kolpen M, Hempel C, Bjarnsholt T, Høiby N, Jensen PØ: Bactericidal Effect of Colistin on Planktonic Pseudomonas Aeruginosa is Independent of Hydroxyl Radical Formation. International Journal of Antimicrobial Agents.
2015Urup T, Dahlrot RH, Grunnet K, Christensen IJ, Michaelsen SR, Toft A, Larsen VA, Broholm H, Kosteljanetz M, Hansen S, Poulsen HS, Lassen U: Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecants treated with bevacizumab and irinotecan. Acta Oncol 2015. n. Acta Oncol 2015. Acta Oncol. 2016 Feb 1:1-5.
2016Urup T, Michaelsen SR, Rønn Olsen LR,Toft A, Christensen IJ, Grunnet K, Winther O, Broholm H, Kosteljanetz M, Issazadeh-Navikas S, Poulsen HS, Lassen U: Angiotensinogen and HLA Class II Predict Bevacizumab Response in Recurrent Glioblastoma Patients.Oncol. 2016 Oct; 10(8):1160-8. doi: 10.1016. PMID: 27262894
2018
Toft A, Urup T, Christensen IJ, Michaelsen SR, Lukram B, Grunnet K, Kosteljanetz M, Larsen AVA, Lassen U, Broholm H, Poulsen HS: Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan. Cancer Invest. 2018 Feb 7;36(2):165-174. doi: 10.1080/07357907.2018.1430818. Epub 2018 Feb 2. Reveiw PMID: 29393706
2018
Jakobsen JN, Urup T, Grunnet K, Toft A, Johansen MD, Poulsen SH, Christensen IJ, Muhic A, Poulsen HS: Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.
J Neurooncol. 2018 Apr;137(2):439-446. doi: 10.1007/s11060-017-2736-x. Epub 2018 Jan 12. PMID: 29330749

 

 Articles submitted:

 

 

 

The Finsencenter, Section 6321, Copenhagen University Hospital, Blegdamsvej 9, DK-2100 Copenhagen, Denmark